Efficacy and safety of allicin in Behcet's disease / 天津医药

ABSTRACT

Objective To evaluate the efficacy and safety of allicin in patients with Behcet's disease (BD). Methods Thirty-eight patients with BD that was mainly involved skin, mucosa and joints were divided into treatment group ( 20 cases) and control group (18 cases) by randomized digital table method. Two groups of patients were respectively assigned to receive allicin tablets and identical placebo vehicles for 12 weeks, and were followed up to 16 weeks. The changes of clinical symp-toms and laboratory detection were observed in the time of pretreatment and post-treatment in two groups. Meanwhile, the ef-ficacy and side effects were compared between both groups. Results A total of 31 patients completed the experiment. The effective rate was 88.89%in treatment group, which was significantly higher than that of the control group (7.69%, P0.05). The levels of ESR and CRP were significant lower in treatment group than those in pretreatment and control group (P < 0.01). Although allicin displayed some adverse reactions, most patients could tolerate them, and these side effects tended to dissipate once the drug ceased. Conclusion Allicin is a safe and effective drug in the treatment of BD, which is significantly better than placebo, and is worth to be further researched and promoted.